皮肤病学中的免疫生物制剂。
Immunobiologicals in dermatology.
机构信息
Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Discipline of Dermatology, Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
出版信息
An Bras Dermatol. 2022 May-Jun;97(3):275-283. doi: 10.1016/j.abd.2021.05.016. Epub 2022 Mar 18.
Abstract
Immunobiologicals are a reality in current clinical practice and have increasingly gained space in the inflammatory disease scenario, especially in dermatology, with approved drugs for psoriasis, atopic dermatitis, and hidradenitis suppurativa, in addition to many others undergoing study. It is important for dermatologists to have knowledge of the medications approved in Brazil, for the best management of dermatoses, in addition to the fact that they represent hope for improvement in patients with chronic diseases.
摘要
免疫生物制剂是当前临床实践中的现实，并在炎症性疾病领域（尤其是皮肤病学领域）日益获得关注，目前已有批准用于治疗银屑病、特应性皮炎和化脓性汗腺炎的药物，此外还有许多其他药物正在研究中。皮肤科医生了解在巴西获得批准的药物对于皮肤病的最佳管理非常重要，此外，这些药物为改善慢性疾病患者的病情带来了希望。
相似文献
1
Immunobiologicals in dermatology.
An Bras Dermatol. 2022 May-Jun;97(3):275-283. doi: 10.1016/j.abd.2021.05.016. Epub 2022 Mar 18.
2
A Practical Guide to Using Biologics in Pediatric Dermatology.
J Cutan Med Surg. 2024 Jan-Feb;28(1):59-67. doi: 10.1177/12034754231222415. Epub 2024 Jan 16.
3
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
4
Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
Dermatol Online J. 2020 Oct 15;26(10):13030/qt0j5150df.
5
[What's New in Dermatological Therapy?].
Ann Dermatol Venereol. 2015 Dec;142 Suppl 3:S49-54. doi: 10.1016/S0151-9638(16)30006-0.
6
Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gut-skin axis and microbiome-directed therapy.
Clin Dermatol. 2023 Sep-Oct;41(5):640-649. doi: 10.1016/j.clindermatol.2023.09.019. Epub 2023 Oct 9.
7
Navigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules.
J Drugs Dermatol. 2018 Dec 1;17(12):1330-1332.
8
Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation.
Int J Mol Sci. 2023 Nov 30;24(23):17014. doi: 10.3390/ijms242317014.
9
Non-psoriatic dermatologic uses of monoclonal antibody therapy.
J Dermatolog Treat. 2009;20(6):319-27. doi: 10.3109/09546630902936778.
10
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
Indian J Dermatol Venereol Leprol. 2021 Mar-Apr;87(2):223-226. doi: 10.4103/ijdvl.IJDVL_455_18.
引用本文的文献
1
Posterior reversible encephalopathy syndrome in a patient treated with ustekinumab.
An Bras Dermatol. 2025 Sep-Oct;100(5):501177. doi: 10.1016/j.abd.2025.501177. Epub 2025 Aug 9.
2
Latent tuberculosis infection in patients with psoriasis using immunobiologicals: an observational study.
An Bras Dermatol. 2025 May-Jun;100(3):563-565. doi: 10.1016/j.abd.2024.09.011. Epub 2025 Apr 16.
3
Treatment patterns and factors associated with discontinuation of monoclonal antibodies.
SAGE Open Med. 2024 Aug 19;12:20503121241271817. doi: 10.1177/20503121241271817. eCollection 2024.
本文引用的文献
1
Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
RMD Open. 2019 Aug 18;5(2):e000990. doi: 10.1136/rmdopen-2019-000990. eCollection 2019.
2
Pemphigus.
Lancet. 2019 Sep 7;394(10201):882-894. doi: 10.1016/S0140-6736(19)31778-7.
3
Remicade (infliximab): 20 years of contributions to science and medicine.
Biologics. 2019 Jul 30;13:139-178. doi: 10.2147/BTT.S207246. eCollection 2019.
4
Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
Acta Derm Venereol. 2019 Oct 1;99(11):971-977. doi: 10.2340/00015555-3245.
5
Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology.
An Bras Dermatol. 2019 Apr;94(2 Suppl 1):20-32. doi: 10.1590/abd1806-4841.2019940206. Epub 2019 Jun 3.
6
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
J Dermatolog Treat. 2020 Mar;31(2):152-159. doi: 10.1080/09546634.2019.1587145. Epub 2019 Mar 19.
7
Anti-IL17 therapies for psoriasis.
Expert Opin Biol Ther. 2019 Jan;19(1):45-54. doi: 10.1080/14712598.2019.1555235. Epub 2018 Dec 8.
8
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
J Drugs Dermatol. 2018 Aug 1;17(8):826-832.
9
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.
10
Chronic Spontaneous Urticaria: The Devil's Itch.
J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1097-1106. doi: 10.1016/j.jaip.2018.04.013.
Zotero 插件